The European Medicines Agency Has Accepted GSK's Application To Expand Use Of Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy (Carboplatin And Paclitaxel) To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has accepted GSK's application to expand the use of Jemperli (Dostarlimab) in combination with standard-of-care chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer. The formal review process will begin soon, with approval expected in the first half of 2025.
June 24, 2024 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The European Medicines Agency has accepted GSK's application to expand the use of Jemperli for endometrial cancer. Approval is expected in H1 2025.
The acceptance of the application by the EMA is a positive regulatory step for GSK. If approved, it could lead to increased sales and market share for Jemperli, positively impacting GSK's revenue and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100